Stoke Therapeutics, Inc. (STOK)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Antisense Oligonucleotide	8.78M	Log In
Antisense Oligonucleotide Growth	-29.22%	Log In

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
United States	8.78M	Log In
United States Growth	-29.22%	Log In